R-Bio

Executive Summary

R-Bio is a U.S. biotechnology company leveraging a proprietary synthetic biology platform to develop and manufacture biosimilar therapeutics, with an initial focus on insulin. Founded in 2018 and based in San Diego, the company aims to reduce insulin costs by 30% and reshore critical pharmaceutical production to the United States. Its lead program, R-biolin, is a biosimilar insulin currently in late preclinical development. The synthetic biology platform enables efficient, scalable manufacturing, potentially offering cost advantages over traditional biologic production methods. The biosimilar insulin market is large and growing, driven by rising diabetes prevalence and demand for affordable alternatives. R-Bio's value proposition centers on cost reduction and domestic production, addressing supply chain vulnerabilities highlighted by recent shortages. The company's late preclinical stage positions it for near-term milestones, including IND filing and clinical trial initiation. If successful, R-biolin could capture significant market share in the insulin biosimilar space, which is currently dominated by a few major players. However, regulatory and competitive risks remain.

Upcoming Catalysts (preview)

• Q4 2026IND Filing for R-biolin70% success
• Q3 2026Series B Financing Round60% success
• Q1 2027Strategic Partnership for Manufacturing50% success